Please login to the form below

Not currently logged in
Email:
Password:

mRNA

This page shows the latest mRNA news and features for those working in and with pharma, biotech and healthcare.

Lilly expands its immuno-oncology work with $1.8bn CureVac deal

Lilly expands its immuno-oncology work with $1.8bn CureVac deal

At the heart of the agreement is messenger RNA (mRNA) technology, marking the first time it has been broadly explored in the immuno-oncology capacity. ... With the aim to drive the potential future vaccines to market, CureVac will take responsibility for

Latest news

  • Merck & Co signs cancer vaccines research deal for Keytruda Merck & Co signs cancer vaccines research deal for Keytruda

    The deal with Moderna Therapeutics will see it use the Cambridge, Massachusetts-based company's novel messenger RNA (mRNA)-based vaccine technology. ... Moderna's mRNA vaccine technology uses the unique mutations present in a patient's tumour to provoke

  • Sanofi forges $1.5bn cancer partnership with BioNTech Sanofi forges $1.5bn cancer partnership with BioNTech

    BioNTech has agreed to supply part of the mRNA material needed for development activities from its in-house manufacturing facility, and has also claimed the right to co-develop and ... commercialise two of the five mRNA therapeutics products with Sanofi

  • mRNA - message received mRNA - message received

    mRNA technology is fundamentally disruptive, enabling us to do things not possible with current approaches. ... and Alexion in mRNA therapeutics and Merck &Co and the Pasteur Institute for mRNA-based vaccines.

  • Dendreon to go to auction without initial bidder Dendreon to go to auction without initial bidder

    Egenix specialises in developing small molecule drugs that block mRNA translation, thus blocking the production of specific proteins that are critical for cancer growth and survival.

  • Boehringer signs €465m lung cancer vaccine deal Boehringer signs €465m lung cancer vaccine deal

    was a really good fit with CureVac's mRNA-based cancer immunotherapy approach. ... for cancer patients and the significant commitment from Boehringer Ingelheim underscores the relevance of the mRNA technology.”.

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Gene therapy Gene therapy

    These early pioneers were largely focused on DNA-based gene delivery or the use of DNA anti-sense technologies to specifically inhibit mRNA translation. ... From a payload perspective, these include new technologies such as siRNA, Sleeping Beauty

  • Deal Watch March 2017 Deal Watch March 2017

    In our Top 20 we have only three: Alexion in-licensed the lipid nanoparticle (LNP) technology from Arbutus Biopharma to use as a delivery technology for an mRNA rare disease product

  • Deal Watch September 2016 Deal Watch September 2016

    At a lower disclosed headline value of $310m BioNTech licensed its mRNA-based cancer vaccines platform to Genentech. ... Licence. mRNA personalised cancer vaccines; $310m upfront and near-term payments. 310+.

  • Deal Watch June 2016 Deal Watch June 2016

    The mRNA vaccines will also be assessed in combination with Keytruda on an exclusive basis. ... licence. 230. Moderna Therapeutics/ Merck &Co. mRNA-based personalised cancer vaccines; exclusive for Keytruda combinations (discovery).

  • Deal Watch November 2015 Deal Watch November 2015

    Sanofi will gain access to BioNTech's mRNA formulation technology to generate new cancer immunotherapies. ... Discover/ develop up to 5 cancer immunotherapies, each a synthetic mRNA mixture.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

  • CureVac’s CEO appointed to EC High Level Group CureVac’s CEO appointed to EC High Level Group

    Dr Ingmar Hoerr, chief executive officer of clinical-stage mRNA technology specialist CureVac, has been appointed to the European Commission's High Level Group for research and innovation programmes. ... As one of the pioneering companies in mRNA

  • CureVac appoints chief financial officer CureVac appoints chief financial officer

    CureVac appoints chief financial officer. Pierre Kemula joins the mRNA company’ s management board. ... Tübingen, Germany-based mRNA firm CureVac has appointed Pierre Kemula as its new chief financial officer.

  • Dr Michael Watson appointed as president of Valera Dr Michael Watson appointed as president of Valera

    Dr Watson said: “ The potential for mRNA therapeutics to meaningfully address some of the world's most pressing infectious disease concerns is truly exciting. “

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
WCG

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics